Efruxifermin Did Not Reduce Fibrosis in MASH-Related Compensated Cirrhosis

(MedPage Today) -- Use of the investigational drug efruxifermin did not significantly reduce fibrosis in patients with compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH) after 36 weeks of treatment, but a longer...